SCHEMBL5095671

SCHEMBL5095671

NNCC1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31327053 0.97
Hydrochloric Acid SCHEMBL359603 0.97
SCHEMBL6072682 0.94
Cimemoxin SCHEMBL2108333 0.91
SCHEMBL10079928 0.91 ADH1B (0.48)
Hydrochloric Acid SCHEMBL360832 0.91 ADH1B (0.42)
SCHEMBL6861640 0.91 ADH1B (0.48)
SCHEMBL26584202 0.91 ADH1B (0.48)
Cimemoxin SCHEMBL359799 0.88 ADH1B (0.46)
Hydrochloric Acid SCHEMBL360226 0.88 ADH1B (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3585500-B1 INTEGRATED PTSA/MEMBRANE METHOD AND SYSTEM FOR H2S AND CO2 REMOVAL FROM BIOGAS AIR LIQUIDE ADVANCED TECH US LLC (US) 2023-08-02 EP disclosed
US-11312688-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-04-26 US disclosed
US-20200308119-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2020-10-01 US disclosed
US-10723703-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-07-28 US disclosed
US-10514610-B2 Lithography patterning with a gas phase resist TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) 2019-12-24 US disclosed
US-20190351176-A1 OXYGEN CONCENTRATOR DAIKIN INDUSTRIES, LTD. (JP) 2019-11-21 US disclosed
US-20190084938-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2019-03-21 US disclosed
US-10183913-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-01-22 US disclosed
EP-2986604-B1 PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2017-12-20 EP disclosed
US-9783477-B2 Synthesis of fuels and feedstocks LOS ALAMOS NATIONAL SECURITY, LLC (US) 2017-10-10 US disclosed
US-20120080490-A1 TISSUE THICKNESS COMPENSATOR COMPRISING DETACHABLE PORTIONS ETHICON ENDO-SURGERY, INC. (US) 2012-04-05 US disclosed
WO-2012008528-A1 PYRAZOLE COMPOUND 大日本住友製薬株式会社 (JP) 2012-01-19 WO disclosed
US-7425552-B2 Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction ANADYS PHARMACEUTICALS, INC. (US) 2008-09-16 US disclosed
US-7425552-B2 Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction ANADYS PHARMACEUTICALS, INC. (US) 2008-09-16 US disclosed
US-7425552-B2 Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction ANADYS PHARMACEUTICALS, INC. (US) 2008-09-16 US disclosed
CN-101137651-A Pyridazinone compounds ANADYS PHARMACEUTICALS INC (US) 2008-03-05 CN disclosed
EP-1824847-A2 PYRIDAZINONE COMPOUNDS Anadys Pharmaceuticals, Inc. (US) 2007-08-29 EP disclosed
US-7205147-B2 Nucleic acids encoding ryanodine receptors E.I. DU PONT DE NEMOURS AND COMPANY (US) 2007-04-17 US disclosed
US-20060189602-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. (US) 2006-08-24 US disclosed
WO-2006066079-A2 PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed